Skip to content

Abbott Laboratories (ABT) Company Overview

Company Analysis

Abbott Laboratories ABT

A comprehensive view of key metrics, scores, and financial health for Abbott Laboratories

Overview of Abbott Laboratories

ABT NYQ
Healthcare Medical Devices Large Cap
Abbott Laboratories (ABT), is a Large Cap company, in the Medical Devices industry, last closed at $108.03, about 48.6% overvalued vs fair value, -15.4% 1Y return, placing in the top 10% of its sector.
$108.03
-0.10%
As of March 13, 2026
Previous close • Vol 90d: 26.2%
52-Week Range
Market Cap
$187.72B
Enterprise Value
$194.27B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Abbott Laboratories.

Top Beats
No strong beats yet

Quick Facts

HQ Abbott Park, IL
Employees 115,000
Fiscal year Dec 31

Next Events

Earnings Apr 15 Estimated
Dividend May 15 Ex-div: Apr 15

Fair Value Snapshot

Bear Base Bull
$50
$56
$62
Current: $108.03 -49% vs base

Engine Room Money Flow™

Large Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$44.3B
5.7%%
Gross Profit
$24.6B
5.9%%
Operating Income
$8.0B
17.9%%
Net Income
$6.5B
-51.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
97.3%
Good

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$5.5B
87.3% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
0/2
Improving
0
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Abbott Laboratories's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
78
/100
Strong
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
81
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing ABT's balance between Growth (19.6%), Profitability (47.6%), and Safety (32.9%). Growth 20% Safety 33% Profitability 48%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

35th percentile vs peers
35
Key Signals
Rev Growth YoY 5.7% 45p Revenue CAGR 3Y 0.5% 28p TSR 12.9% 69p EPS CAGR 3Y -1.7% 27p EPS Growth YoY -51.3% 15p
  • Interest Coverage Ratio in top 20% of peers (25.83, 91th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Operating Margin in top 20% of peers (18.2%, 91th percentile)
  • Roic in top 20% of peers (8.7%, 82th percentile)
  • Eps Growth Yoy in bottom 20% of peers (-51.3%)
  • Growth below peer median (percentile: 35)

Profitability

85th percentile vs peers
85
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

58th percentile vs peers
59
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Abbott Laboratories.

Loading scenario defaults...
Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$55.54
- - -
-48.6% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info